CoChat
Sign Up
Cited by 294Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab

Open access
Toi, Yukihiro, Sugawara, Shunichi, Kawashima, Yosuke, Aiba, Tomoiki, Kawana, Sachiko, Saito, Ryohei, Tsurumi, Kyoji, Suzuki, Kana, Shimizu, Hisashi, Sugisaka, Jun, Ono, Hirotaka, Domeki, Yutaka, Terayama, Keisuke, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Honda, Yoshihiro·2018·The Oncologist
DOI 10.1634/theoncologist.2017-0384PMC PMC6291330
Open this paper in CoChat — free account

Abstract

Background: Immune-related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study aimed to evaluate whether the development of irAEs correlates with treatment response in advanced non-small-cell lung cancer (NSCLC). Patients and Methods: We conducted a retrospective study of patients who received nivolumab monotherapy at Sendai Kousei Hospital (n = 70). The patients were categorized into two groups based on the incidence of irAEs: those with irAEs (irAE group) or those without (non-irAE group). Treatment efficacy was evaluated in each group. The patients were further categorized into responders and nonresponders, and predictive factors of treatment response were determined. Results: The objective response rate was 57% in the irAE group versus 12% in the non-irAE group. Median progression-free survival was 12.0 months in the irAE versus 3.6 months in the non-irAE group. The incidence of both irAEs and pre-existing antithyroid antibody was significantly higher in responders than in nonresponders. Multivariate analysis identified incidence of irAEs and pre-existing antithyroid antibody as an independent predictor of treatment response. Conclusion: Objective response rate and progression-free survival were significantly better in the irAE than in the non-irAE group in patients with advanced NSCLC treated with nivolumab monotherapy. The development of irAEs was associated with clinical efficacy, and the presence of pre-existing antithyroid antibody might be correlated with treatment response to nivolumab monotherapy. Implications for Practice: Immune-related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study evaluted whether the development of irAEs correlates with treatment response in advanced non-small-cell lung cancer. Results showed that the objective response rate and progression-free survival were significantly better in the patients who developed irAEs than in the patients who did not develop irAEs, and the incidence of irAEs and positivity for antithyroid antibody at pretreatment were independent predictors of treatment response of nivolumab monotherapy. Therefore, the development of irAEs predicts clinical benefit and suggests that cautious management of irAEs can lead to achieving maximum clinical benefit from nivolumab monotherapy.

Overview

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2017-0384

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

Sorted by citations

Items 201–294 of 294

Related

See all

Metadata

Authors
Toi, Y., Sugawara, S., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Tsurumi, K., Suzuki, K., Shimizu, H., Sugisaka, J., Ono, H., Domeki, Y., Terayama, K., Nakamura, A., Yamanda, S., Kimura, Y., & Honda, Y.
Affiliations
  • Sendai Kousei Hospital (JP)
  • Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan
Corresponding author
Sugawara, Shunichi
ORCID
Venue
The Oncologist
Publisher
Oxford University Press (OUP)
Published
2018-06-22
Volume
23
Issue
11
Pages
1358-1365
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
DOI
10.1634/theoncologist.2017-0384
PMC
PMC6291330
OpenAlex
W2809615201
Cited by
294
References
33
Citations by year
2026: 11 · 2025: 18 · 2024: 54 · 2023: 46 · 2022: 32 · 2021: 50 · 2020: 47 · 2019: 34 · 2018: 2
FWCI
12.47
Type
journal article
Language
en
Open access
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • The Oncologist (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
immune-related adverse events, nivolumab, non-small cell lung cancer, immune checkpoint inhibitors, treatment response prediction, thyroid autoantibodies, objective response rate, progression-free survival, predictive biomarkers
MeSH terms
Nivolumab, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Middle Aged, Retrospective Studies, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review